The deadline for proposal submission for 2016 has passed. Global Lyme Alliance (GLA) thanks all who applied, and will be in touch with applicants after proposals have been reviewed
GLA has modeled its grants division after that of the National Institutes of Health (NIH). GLA parallels the RO1 and RO3 grant categories in this way:
The Grant Review Committee (GRC) of the SAB is responsible for reviewing all applications. The Financial Review Committee (FRC) is available to advise in the event of any conflicts of interest or issues of commercial application. Once again, the process parallels that of the NIH. GLA’s scientific team, composed of the Chief Scientific Officer and the in-house Science Officer, review the applications to assure their completion. Applications are then sent to the GRC for review.
The GRC evaluates projects both quantitatively and qualitatively. An overall quantitative score is given on a scale of 1 to 10; 1-strong, nearly flawless application; 5-average application; 10-poor application with major shortfalls.
GRC members are experts in their fields. Should additional peer review be necessary, grant applications are sent to esteemed members of the GLA’s peer review board.
Once the entire grant review process is completed, the committee meets to discuss and prioritize the grant application award list in conjunction with the monies available, as assigned by GLA’s Executive Committee. The GRC makes its recommendations to the GLA Board of Directors, who make final decisions following majority approval of these recommendations.
All grant recipients are required to sign a Research Grant Agreement, created to protect both the grant recipient(s) and GLA. These agreements are tailored to each individual grant and are subject to negotiation. Monies are only awarded to a medical institution, foundation, or university, never to an individual. GLA accepts no higher than 3% indirect costs.